Analyst Valuation and EPS Growth for Bridgford Foods (NASDAQ:BRID)

Earnings results for Bridgford Foods (NASDAQ:BRID)

Bridgford Foods Corporation is estimated to report earnings on 03/12/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $0.2.

Bridgford Foods last issued its quarterly earnings results on January 15th, 2021. The reported $0.21 earnings per share (EPS) for the quarter. The business earned $66.67 million during the quarter. Bridgford Foods has generated $0.00 earnings per share over the last year and currently has a price-to-earnings ratio of 21.8. Bridgford Foods has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, March 12th, 2021 based off prior year’s report dates.

Analyst Opinion on Bridgford Foods (NASDAQ:BRID)

Dividend Strength: Bridgford Foods (NASDAQ:BRID)

Bridgford Foods does not currently pay a dividend. Bridgford Foods does not have a long track record of dividend growth.

Insiders buying/selling: Bridgford Foods (NASDAQ:BRID)

In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock. Only 2.80% of the stock of Marinus Pharmaceuticals is held by insiders. 79.32% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Bridgford Foods (NASDAQ:BRID

Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($2.76) to ($2.00) per share. The P/E ratio of Marinus Pharmaceuticals is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Marinus Pharmaceuticals is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Marinus Pharmaceuticals has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here